Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Smiths Medical infusion pump safety

This article was originally published in The Gray Sheet

Executive Summary

Firm's CADD-Sentry Pro medication safety software gains 510(k) clearance, Smiths Medical announces Jan. 29. The software, for use with the firm's CADD-Prizm PCS II ambulatory infusion pump, enables clinicians to program pain therapy protocols via a hospital's computer network before downloading them to the pump instead of programming pumps individually. The software also incorporates bar code verification as an additional safety feature. FDA has highlighted the importance of human factors engineering in infusion pumps to reduce programming errors after seizing pumps from Baxter (Colleague) and Cardinal Health (Alaris SE) (1"The Gray Sheet" Sept. 4, 2006, p. 3)...
Advertisement

Related Content

Cardinal Health Is Second Infusion Pump Maker To Be Hit By An FDA Seizure
Cardinal Health Is Second Infusion Pump Maker To Be Hit By An FDA Seizure
Advertisement
UsernamePublicRestriction

Register

MT024467

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel